Latest Conference Articles

June 22nd 2018, 10:48pm

ESMO Gastrointestinal Cancers Congress

TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.

June 22nd 2018, 10:36pm

ESMO Gastrointestinal Cancers Congress

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

June 22nd 2018, 10:27pm

ESMO Gastrointestinal Cancers Congress

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

June 22nd 2018, 10:01pm

ESMO Gastrointestinal Cancers Congress

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

June 22nd 2018, 9:11pm

ESMO Gastrointestinal Cancers Congress

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

June 21st 2018, 10:49pm

ESMO Gastrointestinal Cancers Congress

TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.

June 21st 2018, 8:56pm

ESMO Gastrointestinal Cancers Congress

Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.

June 21st 2018, 7:02pm

ESMO Gastrointestinal Cancers Congress

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

June 21st 2018, 7:02pm

ESMO Gastrointestinal Cancers Congress

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

June 21st 2018, 12:44am

ESMO Gastrointestinal Cancers Congress

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.

June 21st 2018, 12:26am

ESMO Gastrointestinal Cancers Congress

TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.

June 20th 2018, 11:33pm

ESMO Gastrointestinal Cancers Congress

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.

June 20th 2018, 9:07pm

ESMO Gastrointestinal Cancers Congress

Treatment with second-line ramucirumab improved median overall survival by 3.1 months compared with placebo in patients with advanced hepatocellular carcinoma with alpha-fetoprotein levels ≥400 ng/ml.

June 20th 2018, 6:25pm

ESMO Gastrointestinal Cancers Congress

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses survival data with modified FOLFIRINOX in pancreatic cancer.

June 20th 2018, 6:24pm

ESMO Gastrointestinal Cancers Congress

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.

June 17th 2018, 9:57pm

European Hematology Association Congress

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

June 17th 2018, 9:27pm

European Hematology Association Congress

David Sallman, MD, assistant member, Moffitt Cancer Center, discusses the combination of APR-246 and azacitidine as a treatment for patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

June 17th 2018, 9:14pm

European Hematology Association Congress

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia.

June 17th 2018, 8:21pm

European Hematology Association Congress

The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

June 17th 2018, 5:08pm

European Hematology Association Congress

The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.